AIM
ARK Investment Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $495M | Buy |
10,182,590
+17,190
| +0.2% | +$836K | 3.63% | 9 |
|
|
2025
Q1 | $346M | Buy |
10,165,400
+1,192,336
| +13% | +$40.6M | 3.46% | 9 |
|
|
2024
Q4 | $353M | Buy |
8,973,064
+1,474,439
| +20% | +$58M | 2.94% | 9 |
|
|
2024
Q3 | $352M | Sell |
7,498,625
-279,911
| -4% | -$13.2M | 3.22% | 9 |
|
|
2024
Q2 | $420M | Sell |
7,778,536
-378,492
| -5% | -$20.4M | 3.73% | 7 |
|
|
2024
Q1 | $556M | Sell |
8,157,028
-379,076
| -4% | -$25.8M | 3.85% | 6 |
|
|
2023
Q4 | $534M | Buy |
8,536,104
+1,372,986
| +19% | +$85.9M | 3.16% | 9 |
|
|
2023
Q3 | $325M | Sell |
7,163,118
-175,329
| -2% | -$7.96M | 2.49% | 15 |
|
|
2023
Q2 | $412M | Sell |
7,338,447
-651,741
| -8% | -$36.6M | 2.73% | 13 |
|
|
2023
Q1 | $361M | Buy |
7,990,188
+160,256
| +2% | +$7.25M | 2.48% | 15 |
|
|
2022
Q4 | $318M | Sell |
7,829,932
-407,190
| -5% | -$16.6M | 2.76% | 13 |
|
|
2022
Q3 | $538M | Sell |
8,237,122
-1,490,409
| -15% | -$97.4M | 3.75% | 7 |
|
|
2022
Q2 | $565M | Buy |
9,727,531
+323,460
| +3% | +$18.8M | 3.34% | 10 |
|
|
2022
Q1 | $590M | Buy |
9,404,071
+316,203
| +3% | +$19.8M | 2.46% | 14 |
|
|
2021
Q4 | $689M | Buy |
9,087,868
+1,502,194
| +20% | +$114M | 2.08% | 15 |
|
|
2021
Q3 | $849M | Sell |
7,585,674
-190,445
| -2% | -$21.3M | 2.04% | 16 |
|
|
2021
Q2 | $1.26B | Sell |
7,776,119
-514,231
| -6% | -$83.2M | 2.34% | 12 |
|
|
2021
Q1 | $1.01B | Sell |
8,290,350
-2,122,626
| -20% | -$259M | 2.01% | 10 |
|
|
2020
Q4 | $1.59B | Buy |
10,412,976
+1,955,656
| +23% | +$299M | 4.24% | 3 |
|
|
2020
Q3 | $707M | Buy |
8,457,320
+1,974,069
| +30% | +$165M | 4.2% | 5 |
|
|
2020
Q2 | $476M | Buy |
6,483,251
+2,197,619
| +51% | +$162M | 5.12% | 4 |
|
|
2020
Q1 | $182M | Buy |
4,285,632
+1,328,997
| +45% | +$56.4M | 4.53% | 5 |
|
|
2019
Q4 | $180M | Buy |
2,956,635
+174,495
| +6% | +$10.6M | 4.54% | 4 |
|
|
2019
Q3 | $114M | Buy |
2,782,140
+57,791
| +2% | +$2.37M | 2.49% | 13 |
|
|
2019
Q2 | $128M | Buy |
2,724,349
+701,332
| +35% | +$33M | 3.23% | 9 |
|
|
2019
Q1 | $72.3M | Buy |
2,023,017
+697,907
| +53% | +$24.9M | 2.06% | 17 |
|
|
2018
Q4 | $37.9M | Sell |
1,325,110
-128,480
| -9% | -$3.67M | 1.54% | 25 |
|
|
2018
Q3 | $64.5M | Buy |
1,453,590
+986,450
| +211% | +$43.7M | 1.95% | 16 |
|
|
2018
Q2 | $27.4M | Buy |
467,140
+394,606
| +544% | +$23.2M | 1.01% | 36 |
|
|
2018
Q1 | $3.32M | Buy |
72,534
+41,146
| +131% | +$1.88M | 0.16% | 69 |
|
|
2017
Q4 | $737K | Buy |
31,388
+5,833
| +23% | +$137K | 0.06% | 106 |
|
|
2017
Q3 | $457K | Buy |
25,555
+12,667
| +98% | +$227K | 0.06% | 115 |
|
|
2017
Q2 | $206K | Buy |
+12,888
| New | +$206K | 0.04% | 97 |
|